Abbott FreeStyle AI Visibility Market Strategy Report - Healthcare and Medical Devices

Answer Capsule

Abbott FreeStyle is the dominant recommendation leader in the Healthcare and Medical Devices category, holding 61.2% valid recommendation coverage in October 2026, 21.5 points ahead of second-place Ascensia CONTOUR. The brand is mentioned in 91.5% of qualified AI observations and appears in the top three recommendations in 53.7% of them. Its clearest strength is top-three placement and overall recommendation volume, while its clearest weakness is a softening raw mention presence rate, down 5.3 points from the July 2026 baseline. The biggest opportunity lies in converting its dominant presence into higher rank-one placement, where Ascensia CONTOUR currently leads at 25.6% versus Abbott FreeStyle's 14.6%.

Who This Report Is For

This report is for Abbott FreeStyle marketing, brand, and commercial strategy leaders who need to understand how AI search and chat platforms are recommending the brand relative to competitors, and where targeted action can strengthen recommendation-stage visibility.

Report Card

Executive Summary

Abbott FreeStyle holds dominant recommendation power in the Healthcare and Medical Devices category. The brand recorded 61.2% valid recommendation coverage in October 2026, the highest of any tracked brand and 21.5 points ahead of Ascensia CONTOUR at 39.7%. This lead widened from 15.5 points at the July 2026 baseline, indicating that Abbott FreeStyle's recommendation position strengthened over the three-month period even as the category remained stable.

The brand's raw mention presence rate was 91.5% in October 2026, meaning Abbott FreeStyle appeared in nearly every qualified AI observation. Of the 332 observations where the brand was present, 262 carried positive framing and 70 were neutral, with zero negative mentions recorded. This produced a net sentiment score of 0.7892, reflecting consistently favorable framing quality across AI-generated responses.

Abbott FreeStyle's strongest cluster is the Brand Recommendation class, which covers discovery and consideration queries such as best glucose monitor and continuous glucose monitoring. Within this cluster, the brand recorded 222 valid recommendations out of 363 qualified observations, the highest absolute count of any tracked brand. Its top-three recommendation rate was 53.7%, and its rank-one rate was 14.6%.

The clearest weakness is the gap between top-three placement and rank-one placement. While Abbott FreeStyle appears in the top three in more observations than any competitor, Ascensia CONTOUR holds the category's highest rank-one rate at 25.6%. This means that when AI systems form a shortlist, Abbott FreeStyle is frequently included but is not always the first recommendation.

The strongest platform signal for Abbott FreeStyle is Perplexity, where the brand achieved 80.77% valid recommendation coverage and a 34.62% rank-one rate. The brand also performed strongly on Copilot, with 64.10% coverage and a 25.64% rank-one rate. On Gemini, Abbott FreeStyle recorded 63.51% coverage and a 14.86% rank-one rate.

The clearest platform gap is ChatGPT, where Abbott FreeStyle's valid recommendation coverage was 38.10%, well below its category-wide average. The brand's rank-one rate on ChatGPT was 9.52%, suggesting that ChatGPT surfaces Abbott FreeStyle less prominently than other platforms in the tracked set.

A secondary risk pattern is the presence of high-severity factual inconsistencies across AI platforms. Sixteen critical or high-severity conflicts were detected for Abbott FreeStyle, spanning pricing, accuracy claims, over-the-counter availability, and Medicare coverage pathways. These inconsistencies appear on the same platforms where the brand is most visible, meaning buyers researching Abbott FreeStyle may encounter contradictory information about cost, device accuracy, and eligibility.

What Abbott FreeStyle Is Winning

Questions This Section Answers

• Which recommendation metrics does Abbott FreeStyle lead in the Healthcare and Medical Devices category?
• How does Abbott FreeStyle's presence and sentiment compare to the next-closest competitor?

Abbott FreeStyle holds the strongest overall recommendation position in the category. Its 61.2% valid recommendation coverage in October 2026 is the highest of any tracked brand and represents a 5.6-point gain from the July 2026 baseline of 55.6%. The brand recorded 222 valid recommendations, more than double the second-place brand's 144.

The brand's top-three recommendation rate of 53.7% is the highest in the category, ahead of Ascensia CONTOUR at 37.5% and Roche Accu-Chek at 21.2%. This indicates that when AI systems generate a recommendation shortlist, Abbott FreeStyle is included in the top three more often than any competitor.

Abbott FreeStyle also leads on raw mention presence, appearing in 91.5% of qualified observations. While this figure declined from 96.8% at the July 2026 baseline, it remains far above Ascensia CONTOUR at 51.5% and Roche Accu-Chek at 39.4%.

The brand recorded zero negative mentions across all 363 qualified observations in October 2026. Its net sentiment score of 0.7892 reflects consistently positive or neutral framing, with no cautionary or unfavorable mentions detected in the qualified set.

On Perplexity, Abbott FreeStyle achieved its strongest platform-specific performance, with 80.77% valid recommendation coverage and a 34.62% rank-one rate. This suggests that Perplexity's AI-generated responses consistently position Abbott FreeStyle as a leading recommendation in the category.

Where Abbott FreeStyle Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Where does Abbott FreeStyle lose the first-position recommendation despite leading on top-three inclusion?
• Which platform is Abbott FreeStyle's weakest, and what does its coverage gap look like?
• What happened to Abbott FreeStyle's raw mention presence since the July 2026 baseline?

The clearest gap for Abbott FreeStyle is rank-one placement. While the brand leads on top-three inclusion at 53.7%, its rank-one rate of 14.6% trails Ascensia CONTOUR's 25.6%. This means that in a significant share of recommendation scenarios, AI systems include Abbott FreeStyle in the shortlist but position Ascensia CONTOUR as the first recommendation.

On ChatGPT, Abbott FreeStyle's valid recommendation coverage was 38.10%, compared to its category-wide average of 61.2%. The brand's rank-one rate on ChatGPT was 9.52%, well below its performance on Perplexity and Copilot. This platform-specific gap suggests that ChatGPT's responses may be drawing on different source patterns or weighting different attributes when forming recommendations.

The brand's raw mention presence declined from 96.8% in July 2026 to 91.5% in October 2026, a 5.3-point drop. While this remains the highest presence rate in the category, the decline indicates that Abbott FreeStyle is appearing in a slightly smaller share of qualified observations even as its recommendation credit rises.

The Pricing and Value and Multi-Brand Comparison clusters registered no qualified observations in October 2026. This means the benchmark cannot yet show how AI systems frame Abbott FreeStyle on cost or in direct head-to-head comparisons. However, the inconsistency data reveals that pricing and comparison questions are being asked and answered outside the qualified set, with conflicting claims about monthly costs, annual costs, and Medicare coverage pathways appearing across platforms.

Biggest Opportunity

Questions This Section Answers

• What is the single biggest opportunity for improving Abbott FreeStyle's AI recommendation position?
• How large is the gap between Abbott FreeStyle's top-three rate and its rank-one rate?

The biggest opportunity for Abbott FreeStyle is to convert its dominant top-three presence into higher rank-one placement. The brand already appears in the top three in 53.7% of qualified observations, but its rank-one rate is 14.6%, meaning there is a 39.1-point gap between top-three inclusion and first-position recommendation.

Closing this gap requires understanding which prompts and platforms produce rank-one placement for Ascensia CONTOUR and ensuring that Abbott FreeStyle's owned and earned content addresses the specific attributes AI systems use to form first-position recommendations. The brand's strong performance on Perplexity, where it achieves a 34.62% rank-one rate, suggests that certain source patterns or content structures already support first-position placement on some platforms.

The inconsistency data also points to a specific opportunity: resolving the pricing and accuracy conflicts that appear across ChatGPT, Copilot, Gemini, AI Mode, and Perplexity. When AI systems provide contradictory information about monthly costs, annual costs, MARD accuracy, and OTC availability, buyers may hesitate or defer to competitors with clearer, more consistent public evidence.

Competitive Landscape

Questions This Section Answers

• How do the six tracked brands compare on top-three rate, rank-one rate, and average recommended rank?
• Which competitor leads on rank-one rate and sentiment despite trailing Abbott FreeStyle overall?

Abbott FreeStyle holds the strongest recommendation-stage position in the Healthcare and Medical Devices category, with Ascensia CONTOUR as the clearest challenger and Roche Accu-Chek, LifeScan OneTouch, Prodigy Diabetes Care, and Trividia Health occupying smaller recommendation footprints.

Average recommended rank covers rank-eligible recommendations only.

Abbott FreeStyle leads on top-three rate and average recommended rank, while Ascensia CONTOUR leads on rank-one rate and net sentiment. The table shows that Abbott FreeStyle is the most frequently shortlisted brand but not the most frequently placed first.

AI Response Inconsistency Alerts

Questions This Section Answers

• Which specific topics and products had the highest rate of conflicting AI responses?
• How do the platform answers disagree about Abbott FreeStyle pricing, accuracy, or Medicare coverage?

Sixteen critical or high-severity factual inconsistencies were detected for Abbott FreeStyle across six AI platforms: ChatGPT, Copilot, Gemini, AI Mode, AI Overviews, and Perplexity. These conflicts span pricing, accuracy claims, over-the-counter availability, and Medicare coverage pathways.

On the topic of monthly cost without insurance, AI platforms provided conflicting information about the FreeStyle Libre 2 sensor. When asked how much the sensor costs per month, ChatGPT stated that cash prices average about $235 for two sensors, or roughly $470 per month, citing the Abbott FreeStyle cost page and a SingleCare article. Copilot stated that the retail price is about $235 for two sensors, which equals $235 per month, citing the Abbott support FAQ, GlucoseIntel, and SingleCare. The same $235 two-sensor price was converted to different monthly figures, an arithmetic contradiction.

A separate pricing conflict emerged on the topic of monthly out-of-pocket cost without insurance. When asked which CGM is the cheapest, Gemini stated that out-of-pocket costs run around $70 to $75 per month for the FreeStyle Libre 3 and 3 Plus, citing GlucoseIntel and Real Food Matters. Perplexity stated that Libre 2 sensors cost around $170 per 14 days and Libre 3 around $160 per 14 days, roughly $320 to $340 per month, citing Biology Insights, Gluroo, and Wired. The same Abbott FreeStyle sensors cannot cost both roughly $70 to $75 per month and roughly $320 to $340 per month for cash-paying customers.

On the topic of MARD accuracy for the FreeStyle Libre 3, AI platforms provided conflicting information. When asked what the most accurate blood sugar monitor is, Gemini stated that the FreeStyle Libre 3 Plus has a MARD of approximately 8.2%, citing DiabetesNet, Medical News Today, and Healthline. Copilot stated that the FreeStyle Libre 3 has a MARD of 7.8% to 7.9% and is the best overall, citing MDS Diabetes, GlucoseIntel, and BetterVitals. The same sensor cannot have both a MARD of approximately 8.2% and a MARD of 7.8% to 7.9%, and the two answers also disagree on which device is more accurate.

A related accuracy conflict appeared on the topic of relative accuracy ranking versus Dexcom G7. When asked what the most accurate blood sugar monitor is, Gemini stated that Dexcom G7 is the top pick with the lowest MARD of 7.7% to 8.2%, while FreeStyle Libre 3 Plus is a strong competitor with comparable accuracy of approximately 8.2%. Copilot stated that FreeStyle Libre 3 is the most accurate CGM at 7.8% to 7.9% MARD, better than Dexcom G7 at 8.2%. Both answers cannot be true simultaneously.

On the topic of over-the-counter status, AI platforms provided conflicting information about the FreeStyle Libre 3. When asked what the most accurate CGM OTC is, ChatGPT stated that FreeStyle Libre 3 Plus is a prescription system, not OTC, and that the OTC Abbott option is Libre Rio, citing Health Device Review, the PCE Consortium, and a Diabetes Care journal article. Perplexity stated that Abbott FreeStyle Libre 3 is sold OTC in some areas as a consumer option, citing BetterVitals, Type2Diabetes, and Wired. A product cannot be both a prescription-only system and an over-the-counter consumer option in the same market.

A separate OTC conflict appeared on the topic of the most accurate OTC CGM. When asked what the most accurate CGM OTC is, ChatGPT stated that Libre Rio is the most accurate OTC CGM with approximately 8.7% MARD, citing Health Device Review, the PCE Consortium, and a Diabetes Care journal article. Perplexity stated that FreeStyle Libre 3 is the most accurate OTC CGM with approximately 7.9% MARD, citing BetterVitals, Type2Diabetes, and Wired. The two answers name different Abbott products as the most accurate OTC CGM, and the Libre 3 is described by ChatGPT as prescription-only.

On the topic of real-time alerts, AI platforms provided conflicting information about the FreeStyle Libre 3 Plus. When asked what the best continuous glucose monitoring devices are, Gemini stated that FreeStyle Libre 3 and Libre 3 Plus have alarms and alerts, citing Real Food Matters, BetterVitals, and DiabetesNet. Copilot stated that FreeStyle Libre 3 Plus has no real-time alerts unless paired with an app, citing Saverite Medical and Best Buy product pages. These are incompatible claims about the device's alert capability.

On the topic of annual cost without insurance, AI platforms provided conflicting information. When asked how much the FreeStyle Libre 2 sensor costs per month, ChatGPT stated that cash prices average about $235 for two sensors, or roughly $470 per month, implying approximately $5,640 per year. Copilot stated that the retail price is about $235 for two sensors, which equals $2,800 to $3,300 per year, citing GlucoSpike. The two annual cost figures cannot both be true.

A separate annual cost conflict appeared on the same topic. When asked how much the FreeStyle Libre 2 sensor costs per month, ChatGPT stated that cash prices average about $235 for two sensors, or roughly $470 per month, implying approximately $5,640 per year. Copilot stated that the retail price is $235 to $280 for two sensors, which equals $1,400 to $3,300 per year, citing SingleCare and GlucoSpike. The two annual cost ranges cannot both be true.

On the topic of monthly cost without insurance, a further conflict appeared. When asked how much the FreeStyle Libre 2 sensor costs per month, Copilot stated that the out-of-pocket price is usually $75 to $150 per month, citing the Abbott support FAQ, GlucoseIntel, and a GlucoseIntel brand page. Copilot also stated in a separate response that the retail price is about $235 for two sensors, which equals $235 per month, citing the same sources. The two monthly cost figures are incompatible for the same scenario.

A related monthly cost conflict appeared on the same topic. When asked how much the FreeStyle Libre 2 sensor costs per month, ChatGPT stated that cash prices average about $235 for two sensors, or roughly $470 per month, citing the Abbott cost page and SingleCare. Copilot stated that the monthly cost typically ranges from $75 to $150, though retail cash prices can be as high as $235 for two sensors, citing the Abbott support FAQ, GlucoseIntel, and SingleCare. The two monthly cost figures cannot both be true.

On the topic of monthly price of FreeStyle Libre 3, AI platforms provided conflicting information. When asked what the cheapest CGM without insurance is, AI Mode stated that the cost is approximately $140 to $180 per month using discount platforms like GoodRx or SingleCare, though some warehouse clubs or manufacturer savings vouchers can occasionally bring cash prices lower, citing GlucoSpike, GlucoseIntel, and a YouTube video. AI Overviews stated that the cost is approximately $70 to $75 per month for a 30-day supply using manufacturer savings cards or big-box pharmacies like Walmart, citing Reddit, Real Food Matters, and GlucoSpike. The two monthly cash-pay prices for the same FreeStyle Libre 3 CGM are incompatible.

On the topic of Medicare coverage pathway, AI platforms provided conflicting information. When asked what the monthly cost of FreeStyle Libre 2 is, AI Mode stated that Medicare coverage varies by specific Part D or Medicare Advantage copays, citing GoodRx, SingleCare, and the Abbott cost page. Copilot stated that the device is covered under Part B durable medical equipment, citing FreeStyle Libre Diabetes, the Abbott support FAQ, and GlucoseIntel. Medicare coverage cannot be primarily under both Part D and Part B for the same CGM, as these are distinct benefit pathways with different eligibility and cost rules.

A further accuracy ranking conflict appeared on the topic of MARD. When asked which is the best continuous glucose monitoring device, AI Mode stated that Dexcom G7 is the best overall for clinical accuracy, citing Type1Strong, Real Food Matters, and Snaq. Copilot stated that Abbott FreeStyle Libre 3 Plus is the most accurate with MARD of approximately 7.8% versus Dexcom G7 at approximately 8.2%, citing Total Diabetes Supply, Vitality Medical, and Tastermonial. Both cannot be the most accurate CGM.

Prompt Evidence

Perplexity / Brand Recommendation Prompt: "What is the best CGM device?" Result: Abbott FreeStyle achieved its strongest platform-specific performance on Perplexity, with 80.77% valid recommendation coverage and a 34.62% rank-one rate, indicating that Perplexity consistently positions the brand as a leading recommendation.

ChatGPT / Brand Recommendation Prompt: "What is the best glucose monitor for home use?" Result: Abbott FreeStyle's valid recommendation coverage on ChatGPT was 38.10%, well below its category-wide average of 61.2%, suggesting that ChatGPT surfaces the brand less prominently than other platforms in the tracked set.

Gemini / Brand Recommendation Prompt: "Which CGM device is best?" Result: Gemini provided conflicting information about the FreeStyle Libre 3 Plus MARD, stating approximately 8.2% in one response while Copilot stated 7.8% to 7.9% in another, creating uncertainty about the device's accuracy positioning.

Copilot / Brand Recommendation Prompt: "How much does the FreeStyle Libre 2 sensor cost per month?" Result: Copilot provided conflicting monthly cost figures across responses, stating $75 to $150 per month in one answer and $235 per month in another, both citing the same Abbott support FAQ and GlucoseIntel sources.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map Abbott FreeStyle's prompt-level visibility across all six tracked platforms, identifying which high-intent prompts produce rank-one placement and which produce top-three-only inclusion.

Phase 2: Recommendation Readiness Plan Prioritize the prompts and platforms where Abbott FreeStyle is present but not recommended first, with specific focus on closing the rank-one gap to Ascensia CONTOUR.

Phase 3: Owned Answer Layer Buildout Strengthen Abbott FreeStyle's owned content to address the specific attributes AI systems use to form first-position recommendations, including accuracy claims, cost clarity, and device comparisons.

Phase 4: Citation / Authority Layer Development Resolve the pricing, accuracy, and availability inconsistencies that appear across platforms by ensuring the public evidence layer presents consistent, authoritative information.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track Abbott FreeStyle's recommendation coverage, rank-one rate, and sentiment across all platforms on a monthly basis, with alerts for any movement beyond normal variation.

Why This Matters

AI presence alone is not enough. Abbott FreeStyle appears in 91.5% of qualified observations, but its rank-one rate is 14.6%, meaning the brand is frequently shortlisted but not always chosen first. In a category where buyers increasingly rely on AI-generated recommendations to form their shortlist, the difference between being included and being recommended first can determine whether a brand enters the consideration set or wins the decision.

The inconsistency data shows that AI systems are providing contradictory information about Abbott FreeStyle's pricing, accuracy, and availability across platforms. When buyers encounter conflicting claims about monthly costs, MARD accuracy, or Medicare coverage, they may defer to competitors with clearer, more consistent public evidence. The next move is targeted correction of the prompt, page, and citation layers that shape how AI systems describe and recommend Abbott FreeStyle.

Core Metrics

Sentiment Score

Questions This Section Answers

• What does Abbott FreeStyle's net sentiment score reflect about how AI systems frame the brand?
• Why is classified sentiment more useful than raw mention counts for AI visibility?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Abbott FreeStyle in October 2026: (262 × 1 + 70 × 0 + 0 × -1) / 332 = 0.7892

This score reflects the framing quality of AI-generated mentions, not customer sentiment. A positive mention indicates that AI systems described Abbott FreeStyle favorably or as a recommended option. A neutral mention indicates factual reference without recommendation framing. A negative mention would indicate cautionary or unfavorable framing.

Unclassified mention counts are misleading because they treat all appearances as equivalent. A positive recommendation, a neutral reference, and a cautionary mention are not equal in commercial impact. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, because a brand that appears frequently but is framed neutrally or negatively may have less recommendation power than a brand that appears less often but is consistently recommended.

Share of voice is a diagnostic metric, not a business KPI. The sentiment score helps distinguish between brands that are visible and brands that are recommended. Abbott FreeStyle's score of 0.7892 indicates that the vast majority of its mentions carry positive framing, with no negative mentions detected in the qualified set.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Abbott FreeStyle's AI recommendation visibility in the Healthcare and Medical Devices category, produced by CiteWorks Studio using data from the LLM Authority Index AI Visibility Market Discovery Index.
2. The reporting month is October 2026, with comparison to the July 2026 baseline and monthly data from August 2026 and September 2026.
3. Six AI platforms were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. The benchmark analyzed 363 qualified observations in October 2026, drawn from 681 total prompt-surface observations and 531 unique questions.
5. The competitor universe includes six tracked brands: Abbott FreeStyle, Ascensia CONTOUR, Roche Accu-Chek, LifeScan OneTouch, Prodigy Diabetes Care, and Trividia Health.
6. One public high-intent cluster was used: Brand Recommendation (C01), covering discovery and consideration queries. The Pricing and Value and Multi-Brand Comparison clusters registered no qualified observations in October 2026.
7. Stage 0 extraction retains the query, AI platform, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources.
8. A mention is defined as any appearance of the brand in a qualified AI observation, regardless of recommendation status or framing.
9. A valid recommendation is defined as an observation where the brand appears in a recommendation shortlist with positive or neutral framing and rank-eligible placement.
10. Brand-level percentages use the 363 qualified observations as the public denominator, not the raw collection of 681 prompts.
11. The benchmark does not measure market share, attributable sales, organic-search ranking, or social mention volume, and does not establish causality from metric movement alone.
12. Sixteen critical or high-severity factual inconsistencies were detected for Abbott FreeStyle across six AI platforms, spanning pricing, accuracy claims, over-the-counter availability, and Medicare coverage pathways.

See How AI Is Recommending Your Brand

The public benchmark shows where Abbott FreeStyle is winning and losing in AI-generated recommendations. A company-level AI visibility audit maps the prompt, platform, competitor, ranking, sentiment, and evidence-source patterns behind the headline coverage figures, turning the benchmark data into a prioritized strategy for strengthening recommendation-stage visibility.